Project Grant R01HL177556
Award Date 9/15/25
Completion Date 6/30/30
Dollars Obligated $539K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40506, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded a $503,637 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Kentucky Research Foundation. This grant, awarded on January 15, 2025, supports research to investigate the mechanisms of thrombosis (blood clots) in patients with COVID-19 infection. The key objectives are to measure changes in the hemostatic (clotting) and fibrinolytic (clot-dissolving) systems in COVID-19 patients from initial...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $542,094 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Kentucky Research Foundation. The grant, awarded on March 18, 2025, aims to advance the preclinical development of a liposomal formulation of the antibiotic azithromycin (L-AZM) for the treatment of cardiac inflammation and remodeling following myocardial infarction. The key objectives are to determine the optimal dose,...
- The University of Kentucky Research Foundation received a $1,398,770 Project Grant from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of HDL-associated serum amyloid A (SAA) in sepsis-induced acute lung injury and mortality. The project aims to test the hypothesis that systemic SAA-HDL resolves sepsis-induced lung injury and mortality by regulating neutrophil infiltration into the injured lung. The research...
- The University of Louisville was awarded a $728,529 project grant by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant will fund research to investigate the relationship between the acute immune response and wound healing processes that occur following a myocardial infarction (MI). The project aims to characterize how "emergency granulopoiesis" - the acute increase in neutrophil production in response...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
- The National Institutes of Health National Heart Lung and Blood Institute awarded a $511,680 Project Grant to the University of Illinois under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund research from February 2021 through August 2021 to investigate mechanisms by which vascular endothelial cells instruct macrophage fate in inflammatory injury. Specifically, the research will examine how endothelial cell Wnt signaling licenses the differentiation of monocytes...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Louisville for $108,030.00 supports research on the role of emergency granulopoiesis in wound healing after myocardial infarction. The key objectives are to determine if myocardial infarction-induced emergency granulopoiesis gives rise to neutrophils with differential function, and if emergency granulopoiesis contributes to post-myocardial infarction...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $135,930 to the University of Connecticut Health Center to investigate the role of the TRPM7 ion channel in macrophage signaling and its impact on the development of atherosclerosis. The research aims to generate macrophage-specific TRPM7 deletion mice and subject them to a high-fat, Western diet atherosclerosis model to determine how in vivo TRPM7 deletion...
- The University of Cincinnati, through its Sponsored Research Services Division, was awarded a $156,276 project grant by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on "Hematopoietic Cells and Chemokine Regulation in Abdominal Aortic Aneurysm Associated Thrombosis". The project, with a performance period from August 1, 2025 to June 30, 2027, aims to investigate the role of platelet activation and...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $425,505 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Louisiana State University Health Sciences Center-Shreveport (LSU Health Sciences Center-Shreveport) to investigate the role of cell-specific Programmed Death-Ligand 1 (PD-L1) in cardiac pathophysiology following ischemic injury and cancer. The project aims to elucidate the specific mechanisms by which fibroblast-specific and myeloid...